stockrow
Saturday 7 November 2026
Export ENGN’s income statement to Excel — free account
enGene Therapeutics Inc
ENGN Healthcare Biotechnology
- EPS
- +17.5%
- Free cash flow
- +28.1%
- Total debt
- +42.1%
Quarter to July 2026, against a year earlier
1.76
0.08
+4.76%
Follow ENGN
Alert me
enGene Therapeutics Inc (ENGN) P/E ratio
enGene Therapeutics Inc has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NKTX Nkarta, Inc. compare | n/m |
| CHRS Coherus Oncology, Inc. compare | n/m |
| FHTX Foghorn Therapeutics Inc. compare | n/m |
| PYPD PolyPid Ltd. compare | n/m |
| CDXS Codexis, Inc. compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HUMA Humacyte, Inc. compare | n/m |
| ARMP Armata Pharmaceuticals, Inc. compare | n/m |
| ENGN enGene Therapeutics Inc | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)